Stocks
Sutro Biopharma, Inc.STRO
NASDAQHealthcareBiotechnology$10.94
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer treatment, with a focus on solid tumors. Its lead candidate, luvelta, targets folate receptor alpha and is in late-stage trials for ovarian and endometrial cancers. Investors track the stock for its pipeline catalysts and potential in the ADC space.
52W Range: $7.15-$43.85
Congressional Interest in Sutro Biopharma, Inc. (STRO)
No congressional trades have been disclosed for Sutro Biopharma, Inc. (STRO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading STRO?
No congressional trades found for this stock.